New hope for tough stomach cancers: testing a powerful Two-Drug combo
NCT ID NCT04342910
Summary
This study is for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after their first round of chemotherapy. It aims to see if a new combination of two drugs (camrelizumab and apatinib) can help people live longer than the current standard chemotherapy options. The study will enroll about 550 participants to compare the two treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital, Academy of Military Medical Sciences
RECRUITINGBeijing, China
Contact
Conditions
Explore the condition pages connected to this study.